{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.3","upperLimit":"47.0","value":"33.9"},{"groupId":"OG001","lowerLimit":"25.7","upperLimit":"70.2","value":"45.5"},{"groupId":"OG002","lowerLimit":"45.9","upperLimit":"57.4","value":"51.7"},{"groupId":"OG003","lowerLimit":"48.3","upperLimit":"79.4","value":"65.0"},{"groupId":"OG004","lowerLimit":"34.0","upperLimit":"78.2","value":"57.1"},{"groupId":"OG005","lowerLimit":"18.8","upperLimit":"59.4","value":"37.5"},{"groupId":"OG006","lowerLimit":"24.1","upperLimit":"51.9","value":"37.3"},{"groupId":"OG007","lowerLimit":"10.8","upperLimit":"38.5","value":"22.5"},{"groupId":"OG008","lowerLimit":"9.6","upperLimit":"41.1","value":"22.6"},{"groupId":"OG009","lowerLimit":"36.3","upperLimit":"50.4","value":"43.3"},{"comment":"95% CI could not be derived due to insufficient events being observed at the time of the analysis.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG011","lowerLimit":"30.2","upperLimit":"59.9","value":"44.7"},{"groupId":"OG012","lowerLimit":"27.2","upperLimit":"72.8","value":"50.0"},{"groupId":"OG013","lowerLimit":"11.3","upperLimit":"52.2","value":"28.6"},{"groupId":"OG014","lowerLimit":"54.7","upperLimit":"79.1","value":"67.7"},{"groupId":"OG015","lowerLimit":"18.7","upperLimit":"81.3","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"302"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"51"},{"groupId":"OG007","value":"40"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"201"},{"groupId":"OG010","value":"20"},{"groupId":"OG011","value":"47"},{"groupId":"OG012","value":"20"},{"groupId":"OG013","value":"21"},{"groupId":"OG014","value":"62"},{"groupId":"OG015","value":"10"}],"units":"Participants"}],"description":"Percentage of participants with disease control assessed by the investigator is reported. Disease control is defined as a BOR of confirmed CR, confirmed PR, or SD based on RECIST v1.1. A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 28 days with no evidence of progression in-between. A confirmed PR is defined as two PRs (\\>= 30% decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) or an un-confirmed PR and an unconfirmed CR that were separated by at least 28 days with no evidence of progression in-between. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with squamous cell carcinoma of the head and neck (SCCHN) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG000","title":"Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG001","title":"Expansion Non-SCCHN HPV Positive Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with non-small-cell lung cancer (NSCLC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG002","title":"Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with hepatocellular carcinoma (HCC Total) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG003","title":"Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with advance cutaneous melanoma (ACM) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG004","title":"Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with uveal melanoma (UM) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG005","title":"Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with gastroesophageal cancer (GEC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG006","title":"Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with triple-negative breast cancer (TNBC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG007","title":"Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with pancreatic adenocarcinoma (PAC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG008","title":"Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with urothelial carcinoma (UC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG009","title":"Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with glioblastoma multiforme (GBM) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG010","title":"Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with ovarian cancer (OC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG011","title":"Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with soft- tissue sarcoma (STS) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG012","title":"Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with small-cell lung cancer (SCLC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG013","title":"Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with microsatellite instability (MSI)-high cancer received IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG014","title":"Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)"},{"description":"Participants with nasopharyngeal carcinoma (NPC) received IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurred first.","id":"OG015","title":"Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)"}],"paramType":"NUMBER","populationDescription":"As-treated population included all participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"From Day 1 through disease progression, study withdrawal, or initiation of another anticancer therapy, whichever occurred first (approximately 5.25 years)","title":"DCR Assessed by Investigator in the Dose-expansion Phase","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}